The original version of this article unfortunately contained a mistake. The corrected details are given below.
In Sect. 5 "Tolerability of Rifamycin SV MMX ® ", the first sentence of the second paragraph should read as:
In the placebo-controlled study, the incidence of treatmentemergent adverse events (TEAEs) did not significantly differ between the rifamycin SV MMX ® (n = 199) and placebo (n = 65) groups (29.6 vs. 38.5% of patients) [13] , with most TEAEs considered to be unrelated to the study medication.
The original article has been corrected.
The original article can be found online at https ://doi.org/10.1007/ s4026 1-019-00808 -2.
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